TheraBionic INC

TheraBionic Inc. is an innovative medical device company specializing in cancer treatment through patented tumor-specific radiofrequency technology. The company manufactures the TheraBionic P1 device, an FDA-approved therapeutic system for advanced hepatocellular carcinoma (HCC)—the most common form of liver cancer—in patients who have failed first and second-line therapies. The TheraBionic P1 delivers amplitude-modulated radiofrequency electromagnetic fields (27.12 MHz) via a spoon-shaped antenna placed on the tongue, enabling systemic delivery of low-level, tumor-specific frequencies from head to toe. Clinical studies spanning over two decades demonstrate efficacy in tumor shrinkage, blocking new cancer cell growth, and improving overall survival rates. The device is compact, portable, and notably free of the debilitating side effects associated with conventional chemotherapy and other cancer treatments. TheraBionic's technology represents a breakthrough in non-toxic, systemic targeted therapy for difficult-to-treat cancers.